Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-TH Antibody (R3A02)

Catalog #:   RHC22902 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM, IF, IHC, WB
Accession: P07101
Overview

Catalog No.

RHC22902

Species reactivity

Human, Rat

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000, WB: 1:500-1:2000

Target

Tyrosine 3-hydroxylase, TYH, Tyrosine 3-monooxygenase, TH

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P07101

Applications

ELISA, FCM, IF, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3A02

Data Image
  • Flow Cytometry
    Flow cytometric analysis of Hela cells using TH mouse mAb (green) and negative control (red).
  • Flow Cytometry
    Flow cytometric analysis of MCF-7 cells using TH mouse mAb (green) and negative control (red).
  • Immunofluorescence
    Immunofluorescence analysis of Hela cells using TH mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using TH mouse mAb with DAB staining.
  • Western blot
    Western blot analysis using TH mouse mAb against SH-SY5Y (1) and PC-12 (2) cell lysate.
  • Western blot
    Western blot analysis using TH mouse mAb against SH-SY5Y (1) and PC-12 (2) cell lysate.
References

Incidence, prevention and management of severe infections in patients undergoing therapy for chronic lymphocytic leukemia., PMID:40536789

First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors., PMID:40536766

Influence of triptans use on anti-CGRP mAbs response: a prospective, cohort study., PMID:40536712

Case report of ischemic stroke in a child secondary to neuroborreliosis., PMID:40536655

Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?, PMID:40536609

It's a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies., PMID:40536585

Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) in Uncontrolled Moderate-To-Severe Asthma., PMID:40536285

Endocrinopathies associated with pediatric common variable immunodeficiency., PMID:40536030

Prognostic Significance of Immunohistochemical Surrogate Molecular Sub-Typing of Small Cell Lung Carcinoma., PMID:40536008

C3 Glomerulonephritis Associated With Unusual IgG4 Antifactor H in IgG4-related Disease., PMID:40535909

Development of Traditional Chinese Medicine in combination with EGFR Inhibitors against Cancer., PMID:40535810

Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond., PMID:40535734

The Novel Use of Daratumumab in the Treatment of Refractory Autoimmune Pulmonary Alveolar Proteinosis., PMID:40535728

Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges., PMID:40535484

Double Trouble: Drug-Induced Autoimmune Hepatitis (AIH)-Primary Biliary Cholangitis (PBC) Overlap Syndrome Triggered by Hydralazine., PMID:40535405

Navigating a Diagnostic Dilemma: A Case Report of Overlapping Presentation of Granulomatosis With Polyangiitis and Tuberculosis., PMID:40535379

Efficacy of intravenous immunoglobulin in recurrent pregnancy loss: a retrospective analysis of patients with abnormal cellular immunity., PMID:40535341

A Case of Surgery for a Giant Popliteal Venous Aneurysm Positive for Heparin-Induced Thrombocytopenia Antibodies with Repeated Acute Pulmonary Embolism., PMID:40535145

Combination of immune checkpoint inhibitors with multi-targeted tyrosine kinase inhibitors for second- or later-line therapy of non-small cell lung cancer: a systematic review and meta-analysis., PMID:40535065

Pro-dermcidin and derivatives as potential therapeutics for lethal experimental sepsis., PMID:40534887

Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis., PMID:40534876

Oral immunotherapy for cow's milk allergy in children: a systematic review and meta-analysis., PMID:40534871

Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report., PMID:40534866

Impact of NF-κB and reactive oxygen species on intracellular BAFF/APRIL expression in ANCA-associated vasculitis: focusing on the effect of resveratrol., PMID:40534862

Clinical and electrophysiological features of adult patients with combined central and peripheral demyelination- a systematic review., PMID:40534858

Serum extracellular vesicle microRNAs as potential biomarkers to predict pembrolizumab response and prognosis in metastatic non-small cell lung cancer patients., PMID:40534853

Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn's disease patients., PMID:40534845

Molecular Tuning of Cyanine 5 Dyes to Improve the Pharmacokinetic Profile of Nanobody-Based Fluorescent Tracers., PMID:40534666

Current state-of-the-art of immunotherapy in follicular lymphoma., PMID:40534532

Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies., PMID:40534489

[Comparison of the efficacy, safety, and cost-effectiveness of trastuzumab biosimilar HLX02 and the originator combined with pertuzumab and chemotherapy in the neoadjuvant treatment of patients with HER-2-positive breast cancer]., PMID:40534267

Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response., PMID:40534172

Effectiveness of islatravir post-exposure prophylaxis after intravenous challenge with simian immunodeficiency virus in rhesus macaques., PMID:40534150

Effective Use of BCMA-Targeting Bispecific T-Cell-Engaging Antibody in Treatment Refractory LRP4-positive Myasthenia Gravis., PMID:40534130

A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor., PMID:40533837

Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment., PMID:40533745

Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer - real-world data from a multicenter German patient population., PMID:40533571

R9AP is a common receptor for EBV infection in epithelial cells and B cells., PMID:40533557

Somatostatin receptor 2 targeting peptide modifications for peptide-drug conjugate treatment of small cell lung cancer., PMID:40533489

Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions., PMID:40533299

Validation of Risk Prediction System for Denosumab-Induced Hypocalcemia with an External Clinical Dataset., PMID:40533172

Transverse myelitis following guselkumab treatment for severe plaque psoriasis., PMID:40533109

Efficient gene delivery to immune cells via a recombinant multifunctional chimeric peptide nanocarrier: Implications in immunotherapy., PMID:40532900

Identifying pathogenic contributors of radiodermatitis ameliorated by Smad7-based targeting in canine and mouse models., PMID:40532891

Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer., PMID:40532664

Amplifying tumor recognition and drug susceptibility by multivalent ApDC assembly to combat with tumor cell heterogeneity., PMID:40532654

Targeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases., PMID:40532576

A Rare Case of Pembrolizumab Induced Pericardial Tamponade in a 77-Year-Old., PMID:40532296

Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer., PMID:40532152

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study., PMID:40532125

Datasheet

Document Download

Anti-TH Antibody (R3A02).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-TH Antibody (R3A02) [RHC22902]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only